Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NYSE: TAK) | Delayed: 20.36 +0.43 (2.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.93 | 52 Week High | $0.55 | |||
| Open | $20.18 | 52 Week Low | $0.55 | |||
| Day High | $20.39 | P/E | N/A | |||
| Day Low | $20.08 | EPS | $-0.20 | |||
| Volume | 3,461,936 | |||||
